JP2015519565A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015519565A5 JP2015519565A5 JP2015511765A JP2015511765A JP2015519565A5 JP 2015519565 A5 JP2015519565 A5 JP 2015519565A5 JP 2015511765 A JP2015511765 A JP 2015511765A JP 2015511765 A JP2015511765 A JP 2015511765A JP 2015519565 A5 JP2015519565 A5 JP 2015519565A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- sample
- cell
- item
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims description 124
- 206010028980 Neoplasm Diseases 0.000 claims description 83
- 201000011510 cancer Diseases 0.000 claims description 65
- 238000011282 treatment Methods 0.000 claims description 40
- 210000004027 cell Anatomy 0.000 claims description 29
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 22
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 22
- 229960000684 cytarabine Drugs 0.000 claims description 22
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 21
- 238000001574 biopsy Methods 0.000 claims description 16
- 230000004044 response Effects 0.000 claims description 16
- 238000002512 chemotherapy Methods 0.000 claims description 15
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical group O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 12
- 229960002756 azacitidine Drugs 0.000 claims description 12
- 230000002559 cytogenic effect Effects 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 239000002458 cell surface marker Substances 0.000 claims description 8
- 230000035772 mutation Effects 0.000 claims description 8
- 230000026731 phosphorylation Effects 0.000 claims description 8
- 238000006366 phosphorylation reaction Methods 0.000 claims description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 8
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 6
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 6
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 6
- 208000034578 Multiple myelomas Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 239000011324 bead Substances 0.000 claims description 6
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 6
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 6
- 230000007608 epigenetic mechanism Effects 0.000 claims description 6
- 239000011159 matrix material Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 229940126074 CDK kinase inhibitor Drugs 0.000 claims description 4
- UGTJLJZQQFGTJD-UHFFFAOYSA-N Carbonylcyanide-3-chlorophenylhydrazone Chemical compound ClC1=CC=CC(NN=C(C#N)C#N)=C1 UGTJLJZQQFGTJD-UHFFFAOYSA-N 0.000 claims description 4
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 4
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims description 4
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 claims description 4
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 claims description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 4
- 102000003964 Histone deacetylase Human genes 0.000 claims description 4
- 108090000353 Histone deacetylase Proteins 0.000 claims description 4
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims description 4
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims description 4
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 claims description 4
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 4
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims description 4
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 4
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 4
- 101001092185 Homo sapiens Regulator of cell cycle RGCC Proteins 0.000 claims description 4
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims description 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 4
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 4
- 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 claims description 4
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 4
- 102100035542 Regulator of cell cycle RGCC Human genes 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical compound C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 claims description 4
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims description 4
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000001973 epigenetic effect Effects 0.000 claims description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 4
- 201000005787 hematologic cancer Diseases 0.000 claims description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 4
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 210000001700 mitochondrial membrane Anatomy 0.000 claims description 4
- 229910052697 platinum Inorganic materials 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 230000022983 regulation of cell cycle Effects 0.000 claims description 4
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 230000035945 sensitivity Effects 0.000 claims description 3
- RZCJYMOBWVJQGV-UHFFFAOYSA-N 2-naphthyloxyacetic acid Chemical compound C1=CC=CC2=CC(OCC(=O)O)=CC=C21 RZCJYMOBWVJQGV-UHFFFAOYSA-N 0.000 claims description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical group O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 108091012583 BCL2 Proteins 0.000 claims description 2
- -1 BCLXL Proteins 0.000 claims description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 claims description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims description 2
- 108091006149 Electron carriers Proteins 0.000 claims description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 2
- 102000010638 Kinesin Human genes 0.000 claims description 2
- 108010063296 Kinesin Proteins 0.000 claims description 2
- 102000002111 Neuropilin Human genes 0.000 claims description 2
- 108050009450 Neuropilin Proteins 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 2
- 238000009098 adjuvant therapy Methods 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- 230000006907 apoptotic process Effects 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 239000000090 biomarker Substances 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 190000008236 carboplatin Chemical compound 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 210000004748 cultured cell Anatomy 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 229960000975 daunorubicin Drugs 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 229960003603 decitabine Drugs 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 230000027721 electron transport chain Effects 0.000 claims description 2
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims description 2
- 229950005837 entinostat Drugs 0.000 claims description 2
- 229960001904 epirubicin Drugs 0.000 claims description 2
- 210000002919 epithelial cell Anatomy 0.000 claims description 2
- 201000003444 follicular lymphoma Diseases 0.000 claims description 2
- 229960000908 idarubicin Drugs 0.000 claims description 2
- 238000003364 immunohistochemistry Methods 0.000 claims description 2
- 238000007901 in situ hybridization Methods 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 210000003470 mitochondria Anatomy 0.000 claims description 2
- 229960001156 mitoxantrone Drugs 0.000 claims description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- 230000000869 mutational effect Effects 0.000 claims description 2
- 239000013642 negative control Substances 0.000 claims description 2
- 238000009099 neoadjuvant therapy Methods 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 231100001143 noxa Toxicity 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 201000003733 ovarian melanoma Diseases 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 239000013641 positive control Substances 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 239000003207 proteasome inhibitor Substances 0.000 claims description 2
- 229940124272 protein stabilizer Drugs 0.000 claims description 2
- 238000001243 protein synthesis Methods 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 claims description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 2
- 230000014616 translation Effects 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims description 2
- 229960000237 vorinostat Drugs 0.000 claims description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 2
- 239000012188 paraffin wax Substances 0.000 claims 1
- 239000000463 material Substances 0.000 description 2
- 230000035572 chemosensitivity Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261645253P | 2012-05-10 | 2012-05-10 | |
| US61/645,253 | 2012-05-10 | ||
| US201361780252P | 2013-03-13 | 2013-03-13 | |
| US61/780,252 | 2013-03-13 | ||
| PCT/US2013/040585 WO2013170176A2 (en) | 2012-05-10 | 2013-05-10 | Surrogate functional diagnostics test for cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017202640A Division JP6748050B2 (ja) | 2012-05-10 | 2017-10-19 | 癌に対する補助的機能診断テスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015519565A JP2015519565A (ja) | 2015-07-09 |
| JP2015519565A5 true JP2015519565A5 (https=) | 2016-06-30 |
Family
ID=49551473
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015511765A Withdrawn JP2015519565A (ja) | 2012-05-10 | 2013-05-10 | がんに対する補助的機能診断テスト |
| JP2017202640A Expired - Fee Related JP6748050B2 (ja) | 2012-05-10 | 2017-10-19 | 癌に対する補助的機能診断テスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017202640A Expired - Fee Related JP6748050B2 (ja) | 2012-05-10 | 2017-10-19 | 癌に対する補助的機能診断テスト |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20150301053A1 (https=) |
| EP (2) | EP2847592A4 (https=) |
| JP (2) | JP2015519565A (https=) |
| KR (1) | KR102062416B1 (https=) |
| CN (3) | CN111856013A (https=) |
| WO (1) | WO2013170176A2 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004022580A2 (en) | 2002-09-09 | 2004-03-18 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
| EP2008106A2 (en) | 2006-03-31 | 2008-12-31 | Dana-Farber Cancer Institute | Methods of determining cellular chemosensitivity |
| HK1213046A1 (zh) | 2012-09-19 | 2016-06-24 | Dana-Farber Cancer Institute, Inc. | 動態bh3分析 |
| WO2015010094A1 (en) * | 2013-07-18 | 2015-01-22 | Eutropics Pharmaceuticals, Inc. | Differential bh3 mitochondrial profiling |
| CA2922503C (en) | 2013-09-19 | 2021-10-26 | Dana-Farber Cancer Institute, Inc. | Methods of bh3 profiling |
| WO2015066305A1 (en) | 2013-10-30 | 2015-05-07 | Eutropics Pharmaceuticals, Inc. | Methods for determining chemosensitivity and chemotoxicity |
| US10793915B2 (en) | 2015-01-12 | 2020-10-06 | Eutropics Pharmaceuticals, Inc. | Context dependent diagnostics test for guiding cancer treatment |
| US20180100859A1 (en) * | 2015-03-24 | 2018-04-12 | Eutropics Pharmaceuticals, Inc. | Surrogate functional biomarker for solid tumor cancer |
| US9901574B2 (en) * | 2015-04-20 | 2018-02-27 | Tolero Pharmaceuticals, Inc. | Predicting response to alvocidib by mitochondrial profiling |
| AU2016253957C1 (en) * | 2015-04-27 | 2021-04-01 | Dana-Farber Cancer Institute, Inc. | High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells |
| ES2739749T3 (es) | 2015-05-18 | 2020-02-03 | Tolero Pharmaceuticals Inc | Profármacos de alvocidib que tienen biodisponibilidad aumentada |
| MX2018001289A (es) | 2015-08-03 | 2018-04-30 | Tolero Pharmaceuticals Inc | Terapias de combinacion para el tratamiento del cancer. |
| CN105653896B (zh) * | 2016-01-22 | 2019-02-12 | 北京圣谷同创科技发展有限公司 | 高通量测序突变检测结果验证方法 |
| EP3273240A1 (en) * | 2016-07-17 | 2018-01-24 | Mitogro OÜ | Method for selecting patients responsive for cancer treatments |
| WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| KR20190099260A (ko) | 2016-12-19 | 2019-08-26 | 톨레로 파마수티컬스, 인크. | 프로파일링 펩티드 및 감도 프로파일링을 위한 방법 |
| US20180293352A1 (en) * | 2017-04-10 | 2018-10-11 | COTA, Inc. | System and Method for Decision-Making for Determining Initiation and Type of Treatment for Patients with a Progressive Illness |
| WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
| US11034710B2 (en) | 2018-12-04 | 2021-06-15 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
| CN109813916A (zh) * | 2019-02-15 | 2019-05-28 | 浠思（上海）生物技术有限公司 | 利用HTRF一步法筛选Bcl-2家族成员之间结合的阻断剂的方法 |
| JP7589159B2 (ja) | 2019-02-26 | 2024-11-25 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | ライブセルイメージング（ｌｉｖｅ ｃｅｌｌ ｉｍａｇｉｎｇ）動的ＢＨ３プロファイリング |
| US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
| EP4168123B1 (en) * | 2020-06-17 | 2025-08-27 | University of Utah Research Foundation | Biomarker based patient selection for proteasome inhibitor treatment |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9704444D0 (en) * | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
| US20030073661A1 (en) * | 2001-09-24 | 2003-04-17 | Shigemi Matsuyama | Method of modulating or examining Ku70 levels in cells |
| WO2004022580A2 (en) * | 2002-09-09 | 2004-03-18 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
| CN1302004C (zh) * | 2003-08-22 | 2007-02-28 | 浙江海正药业股份有限公司 | 一种阿糖胞苷的制备方法 |
| CN1981872B (zh) * | 2005-12-12 | 2012-01-25 | 中国医学科学院肿瘤研究所 | Puma在肿瘤放化疗增敏中的新用途 |
| EP2008106A2 (en) * | 2006-03-31 | 2008-12-31 | Dana-Farber Cancer Institute | Methods of determining cellular chemosensitivity |
| WO2008021484A2 (en) | 2006-08-16 | 2008-02-21 | Eutropics Pharmaceuticals | Assay system to identify therapeutic agents |
| US8168755B2 (en) | 2008-05-07 | 2012-05-01 | Eutropics Pharmaceuticals, Inc. | Antibodies specific to heterodimers of Bcl-2 family and uses thereof |
| MX2011008488A (es) * | 2009-02-11 | 2011-10-24 | Abbott Lab | Metodos y composiciones para identificar, clasificar y monitorear individuos que tienen tumores y canceres resistentes al inhibidor de la familia de bcl-2. |
| WO2012088438A1 (en) | 2010-12-22 | 2012-06-28 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
| US9051305B2 (en) | 2011-03-08 | 2015-06-09 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
| EP2660746A1 (en) * | 2012-04-30 | 2013-11-06 | Royal College of Surgeons in Ireland | Dose-response medical outcome model predictor system and method |
| WO2015010094A1 (en) * | 2013-07-18 | 2015-01-22 | Eutropics Pharmaceuticals, Inc. | Differential bh3 mitochondrial profiling |
| WO2015066305A1 (en) * | 2013-10-30 | 2015-05-07 | Eutropics Pharmaceuticals, Inc. | Methods for determining chemosensitivity and chemotoxicity |
| US20180100859A1 (en) * | 2015-03-24 | 2018-04-12 | Eutropics Pharmaceuticals, Inc. | Surrogate functional biomarker for solid tumor cancer |
-
2013
- 2013-05-10 KR KR1020147034524A patent/KR102062416B1/ko not_active Expired - Fee Related
- 2013-05-10 JP JP2015511765A patent/JP2015519565A/ja not_active Withdrawn
- 2013-05-10 EP EP13787323.8A patent/EP2847592A4/en not_active Withdrawn
- 2013-05-10 CN CN202010528293.6A patent/CN111856013A/zh active Pending
- 2013-05-10 WO PCT/US2013/040585 patent/WO2013170176A2/en not_active Ceased
- 2013-05-10 CN CN201710356313.4A patent/CN107315088A/zh active Pending
- 2013-05-10 CN CN201380036422.8A patent/CN104541170A/zh active Pending
- 2013-05-10 US US14/440,762 patent/US20150301053A1/en not_active Abandoned
- 2013-05-10 EP EP17159039.1A patent/EP3236262B1/en active Active
-
2017
- 2017-10-19 JP JP2017202640A patent/JP6748050B2/ja not_active Expired - Fee Related
- 2017-11-03 US US15/803,148 patent/US20180246106A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015519565A5 (https=) | ||
| JP2018503092A5 (https=) | ||
| Chen et al. | Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study | |
| JP6748050B2 (ja) | 癌に対する補助的機能診断テスト | |
| Goeppert et al. | Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer | |
| Stoetzer et al. | Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy | |
| Leslie et al. | A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study | |
| Bartkowiak et al. | Discovery of a novel unfolded protein response phenotype of cancer stem/progenitor cells from the bone marrow of breast cancer patients | |
| Kotowicz et al. | The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease | |
| Ali et al. | PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers | |
| Turashvili et al. | P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer | |
| Cartron et al. | Prognostic impact of the expression/phosphorylation of the BH3-only proteins of the BCL-2 family in glioblastoma multiforme | |
| Javid et al. | Extracellular cytochrome c as a biomarker for monitoring therapeutic efficacy and prognosis of non-small cell lung cancer patients | |
| JP5548694B2 (ja) | 抗がん剤の感受性の判定方法 | |
| JP2016538539A5 (https=) | ||
| Bevilacqua et al. | A “live” biopsy in a small-cell lung cancer patient by detection of circulating tumor cells | |
| Betof et al. | Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification | |
| JPWO2009096196A1 (ja) | 抗がん剤感受性の判定方法 | |
| Hanaoka et al. | Correlation between tumor mesothelin expression and serum mesothelin in patients with epithelial ovarian carcinoma: a potential noninvasive biomarker for mesothelin-targeted therapy | |
| Sahin Ozkan et al. | Prognostic role of immune markers in triple negative breast carcinoma | |
| Caldeira et al. | Immunophenotype of neutrophils in oral squamous cell carcinoma patients | |
| Xiao et al. | Clinicopathological characteristics and prognosis of metaplastic carcinoma of the breast | |
| Kim et al. | Cytokeratin 17 expression is associated with poor prognosis in gallbladder adenocarcinoma | |
| Kramer et al. | A pro-apoptotic function of iASPP by stabilizing p300 and CBP through inhibition of BRMS1 E3 ubiquitin ligase activity | |
| WO2007011372A2 (en) | Therapeutic and prognostic factor yy1 in human cancer |